- ►ascopubs.org RF Ozols, BN Bundy, BE Greer, JM Fowler, D … - Journal of Clinical …, 2003 - jco.ascopubs.org Purpose: In randomized trials the combination of cisplatin and paclitaxel was superior to cisplatin
and cyclophosphamide in advanced-stage epithelial ovarian cancer. Although in nonrandomized trials,
carboplatin and paclitaxel was a ... Cited by 509 - Related articles - BL Direct - All 11 versions
- ►oxfordjournals.org [PDF] SA Rosenberg, JR Yannelli, JC Yang, SL … - JNCI Journal of the …, 1994 - jnci.oxfordjournals.org Background: Studies of human tumor- infiltrating lymphocytes (TILs) derived from patients with a
variety of his- tologic types of cancer have demon- strated that cellular immune reactions against
established malignancy exist in ... Cited by 494 - Related articles - BL Direct - All 7 versions
- ►oxfordjournals.org [PDF] SA Rosenberg, MT Lotze, JC Yang, SL … - JNCI Journal of the …, 1993 - jnci.oxfordjournals.org Background: Treatment using interleukin-2 (IL-2) alone or in conjunction with lymphokine-activated
killer (LAK) cells has been shown to mediate disease regression in selected patients with advanced
cancer. Purpose: This prospective ... Cited by 356 - Related articles - BL Direct - All 6 versions
- ►nih.gov [PDF] JB Hibbs Jr, C Westenfelder, R Taintor, Z … - Journal of Clinical …, 1992 - pubmedcentral.nih.gov Aninterferon-'y,tumornecrosis factor, and interleukin-1-induc- ible, high-output pathway
synthesizing nitric oxide (NO) from L-arginine was recently identified in rodents. High-dose inter-
leukin-2 (IL-2) therapy is known to ... Cited by 334 - Related articles - All 6 versions
- ►jcojournal.org [PDF] JP Siegel, RK Puri - Journal of Clinical Oncology, 1991 - jcojournal.org INTERLEUKIN-2 (IL-2) is a pleiotropic lym- phokine with the ability to support T-cell proliferation,
augment natural-killer (NK)-cell cy- totoxicity, induce lymphokine-activated killer (LAK) cell
development, and participate in the ... Cited by 330 - Related articles - All 7 versions
- ►rupress.org [PDF] P Marrack, M Blackman, E Kushnir, J … - Journal of Experimental …, 1990 - jem.rupress.org A group of toxins produced by Staphylococcus aureus has long been known to be responsible for a
number ofhuman diseases, including food poisoning and toxic shock (1, 2). It is also known that
these toxins are powerful ... Cited by 241 - Related articles - All 4 versions
- ►ascopubs.org [PDF] RE Lee, MT Lotze, JM Skibber, E Tucker, RO … - Journal of Clinical …, 1989 - jco.ascopubs.org From the Surgery Branch, National Cancer Institute; the Critical Care and Nuclear Medicine
Departments, Clinical Center, and the Cardiology Branch, National Heart, Lung and Blood Institute,
National Institutes of Health, ... Cited by 162 - Related articles - All 6 versions
- ►nih.gov [PDF] SA Rosenberg - Annals of surgery, 1988 - pubmedcentral.nih.gov Recent increases in knowledge of cellularimmunology, com- bined with developments in biotechnology,
have provided new opportunities for the development of immunotherapies for the treatment of cancer
in humans. One approach to therapy ... Cited by 154 - Related articles - All 4 versions
- ►ascopubs.org JI Clark, MB Atkins, WJ Urba, S Creech, RA … - Journal of Clinical …, 2003 - jco.ascopubs.org Patients and Methods: Eligibility requirements were resected locally advanced (LA; T3b-4 or N1–3)
or metastatic (M1) RCC, no prior systemic therapy, and excellent organ function. Randomized
assignment was to one course of ... Cited by 144 - Related articles - BL Direct - All 7 versions
- ►adisonline.com [PDF] PE Kintzel - Drug Safety, 2001 - ingentaconnect.com Abstract Nephrotoxicity is an inherent adverse effect of certain anticancer drugs. Renal dysfunction
can be categorised as prerenal uraemia, intrinsic damage or postrenal uraemia according to the
underlying pathophysiological ... Cited by 138 - Related articles - BL Direct - All 8 versions
